

---

# Spontaneous Abortion

Etiologic mechanisms • Placental context • Clinicopathologic reasoning

---

Pathology lecture

**Dr Abu Suraih Sakhri**

MBBS, MD (Pathology)

[www.abusuraihsakhri.com](http://www.abusuraihsakhri.com)

# Learning objectives

**By the end of this lecture, you should be able to:**

- Define spontaneous abortion using the gestational boundary stated.
- Interpret the reported frequencies without mixing different denominators.
- Organize fetal and maternal etiologic contributors into mechanistic domains.
- Relate pregnancy loss to the maternal–fetal interface and interpret uncertainty.

# Miscarriage: The textbook definition

## Spontaneous abortion = miscarriage

- Pregnancy loss before 20 weeks of gestation (the boundary used in this source).
- The term describes the outcome, not a single etiologic disease.
- The source identifies numerous fetal and maternal contributors.


### Terminology

The gestational threshold is edition- and jurisdiction-dependent; This lecture uses the explicit Robbins definition.

Definition is an outcome category; Causation requires separate analysis.

# Gestational timing: The reported distribution

*Time window adapted to the source statement; Not drawn to scale*



The source emphasizes concentration in the earliest part of pregnancy.

# Clinically recognized pregnancies

**10–15%**

**Terminate in spontaneous  
abortion**

- The percentage refers to clinically recognized pregnancies.
- Not all conceptions are clinically detected.
- Interpret this frequency within its explicitly defined denominator.

**Do not treat this estimate as a percentage of all conceptions.**

## Additional early losses detected by sensitive assays

**~20%**

**Additional early pregnancies  
terminate spontaneously**

- Sensitive chorionic gonadotropin assays detect losses not routinely recognized.
- These in otherwise healthy females.
- This is a distinct ascertainment context from clinically recognized pregnancy.

**An additional early-loss estimate; Denominators are not interchangeable.**

## Frequency statements have different denominators

| Observation       | Population / detection                               | What to infer                                     |
|-------------------|------------------------------------------------------|---------------------------------------------------|
| 10–15%            | Clinically recognized pregnancies                    | Frequency after clinical recognition              |
| Additional ~20%   | Early pregnancy recognized with sensitive hCG assays | Earlier losses can escape clinical recognition    |
| Most before 12 wk | Spontaneous abortions                                | Early gestations dominate the timing distribution |

Ascertainment method matters when interpreting pregnancy-loss epidemiology.

# Pregnancy loss is etiologically heterogeneous

## **One clinical outcome; Multiple potential biological routes**

- Fetal genetic abnormalities are prominent in early abortuses.
- Maternal endocrine, structural, vascular, infectious and immune factors also appear.
- These categories describe possible contributors, not mutually exclusive diagnoses.

Different pathways may converge on inability to maintain gestation.

# Six major etiologic domains in the source

## Fetal genetics

Aneuploidy • polyploidy • translocations

## Maternal endocrine

Luteal-phase defect • diabetes

## Uterine anatomy

Leiomyoma • polyp • malformation

## Maternal vasculature

APS • coagulopathy • hypertension

## Infection

Protozoa • bacteria • viruses

## Immune tolerance

Innate/adaptive balance • regulatory T cells

# An unknown mechanism is a valid outcome

## Causal assignment has limitations

- The mechanism of most individual early losses is unknown.
- Identifying a potential contributor does not prove it caused one specific loss.
- The lecture separates source-established categories from explanatory teaching schematics.

### Inference discipline

Association, biologic plausibility and demonstrated individual causation are different evidentiary levels.

**Do not transform a risk category into a case-specific diagnosis.**

# Fetal and maternal domains: An organizing distinction

## The clinical endpoint does not specify the compartment

- Fetal: Chromosomal abnormalities and additional genetic defects.
- Maternal: Endocrine environment, uterine anatomy, vascular status and infection.
- Interface: Placentation and maternal tolerance of fetal trophoblast.

### Why this matters

A category-specific problem can arise before, during, or after implantation.

Partition the potential mechanism before interpreting the clinical finding.

# Placental biology provides essential context

## Maternal and fetal structures are functionally coupled

- Chorionic villi form branching exchange structures.
- Villous trophoblast mediates transport, hormonal secretion and barrier function.
- Invasive extravillous trophoblast establishes maternal attachment and vascular remodeling.

Normal placental development depends on both fetal-derived tissue and maternal response.

# The trophoblast lineage has distinct functions

## Cytotrophoblast

---

Villus-covering epithelial component

Forms a discrete layer in early villi

## Syncytiotrophoblast

---

Villus-covering epithelial component

Exchange, hormone secretion, barrier

## Extravillous trophoblast

---


Invasive placental cells

Anchors placenta and remodels vessels

Do not conflate the villous exchange surface with invasive extravillous cells.

# Normal early chorionic villus: Tissue architecture

*Native schematic — not a histologic image*



Early villi have two distinguishable trophoblast layers around central stroma.

# First-trimester villi have two epithelial layers

## Description of the normal reference architecture

- A delicate central stromal mesh occupies the villus core.
- An inner layer of cytotrophoblast is readily identifiable.
- An outer syncytiotrophoblast layer surrounds the cytotrophoblast.

The parent textbook figure depicts normal tissue—not a specific miscarriage lesion.

# The mature villus has a thinner exchange barrier

## Gestational remodeling changes normal morphology

- By the third trimester, villous capillaries form a dense, dilated network.
- Syncytiotrophoblast becomes thin near fetal capillary endothelium.
- The cytotrophoblast layer is substantially diminished.

Do not compare villi from different gestational ages as though they share identical baseline morphology.

# Maternal and fetal circulations remain distinct

*Original conceptual diagram — no mixing under normal circumstances*

## MATERNAL CIRCULATION

Spiral arteries → intervillous blood

## FETAL CIRCULATION


Umbilical arteries → villous  
capillaries

**Exchange across trophoblast + capillary interface**

Maternal blood occupies the intervillous space; Fetal blood remains within fetal vessels.

# Maternal perfusion reaches the intervillous space

*Conceptual pathway (schematic)*




The parent chapter places the onset of maternal blood entry at approximately 10–12 weeks.

Maternal blood remains outside fetal vessels in a normal placenta.

# Fetal vessels follow a separate route


*Conceptual pathway (schematic)*



Maternal and fetal circulations are juxtaposed for exchange but normally remain separate.

# Extravillous trophoblast and the uterine vessel

*Conceptual pathway (schematic)*



Successful placentation relies on carefully regulated invasion and maternal vascular adaptation.

This is normal physiology; It is not proof of a specific mechanism in a given miscarriage.

# What does this source establish about morphology?

## **Normal placental structure is described; Miscarriage morphology is not**

- The adjacent parent section describes normal villi and placental circulation.
- The spontaneous-abortion section principally lists etiologic categories.
- It does not provide a validated histologic pattern or diagnostic tissue criterion for each mechanism.

**A diagnostic photomicrograph cannot be invented to fill a source gap.**

# Fetal chromosomal abnormalities are prominent

## Genomic defects form the largest quantified category in this excerpt

- Aneuploidy, polyploidy and translocations.
- These abnormalities are reported in approximately half of early abortuses.
- Additional, subtler genetic defects may be missed by routine testing.

A chromosomal result is informative, but not every loss is chromosomally explained.

# Chromosomal findings in early abortuses

**~50%**

**Have fetal chromosomal  
anomalies**

- The observation concerns examined early abortuses.
- The named examples are aneuploidy, polyploidy and translocations.
- It does not assert that 50% of all pregnancies have such anomalies.

**The 50% figure is not a maternal risk estimate or a predicted individual recurrence rate.**

# Aneuploidy: Abnormal chromosome number

## A fetal genomic category explicitly named in the source

- Aneuploidy refers to gain or loss of individual chromosomes.
- It belongs to the group of chromosomal abnormalities reported in early abortuses.
- The source does not specify the frequency of any individual trisomy or monosomy.

### Interpretive point

A genetic category can explain a failed gestation without identifying a maternal disorder.

Avoid inventing chromosome-specific proportions.

# Polyploidy: Alteration of whole chromosome sets

## Different from gain or loss of a single chromosome

- Polyploidy denotes additional complete chromosome complements.
- It is one of the three examples of chromosomal anomalies in early abortuses.
- The Robbins excerpt does not assign a separate rate or a characteristic morphology.

### Comparison

Aneuploidy alters individual chromosome number;  
Polyploidy alters complete chromosome sets.

# Translocations: Chromosomal rearrangements

## Structural chromosome changes are a distinct category

- Translocations rearrange chromosome segments between chromosomes.
- They are included among abnormalities found in early abortuses.
- The excerpt provides no subclassification, parental carrier rate or recurrence estimate.

The presence of a rearrangement category does not justify case-specific counseling numbers.

## Three chromosomal categories: Do not conflate

| Category      | Basic genetic change                  | Textbook claim           |
|---------------|---------------------------------------|--------------------------|
| Aneuploidy    | Abnormal individual chromosome number | Named in early abortuses |
| Polyploidy    | Altered number of chromosome sets     | Named in early abortuses |
| Translocation | Chromosome segment rearrangement      | Named in early abortuses |

These are classification examples; The excerpt does not rank them individually.

## More subtle fetal genetic defects may escape detection

### **A normal routine result does not establish genetic normality**

- An additional fraction of early loss from subtle genetic defects.
- Routine genetic testing may not be available for these defects.
- The source does not quantify that additional fraction.

Do not force every unexplained loss into the measured chromosomal category.

# Interpreting a genetic result requires restraint

## Distinguish observation from an etiologic conclusion

- A chromosomal abnormality in abortus tissue supplies mechanistic evidence.
- A measured proportion in early abortuses does not determine the cause of every loss.
- Test availability and resolution constrain the interpretation.

### Reporting discipline

Describe what was demonstrated and what remains unresolved.

Source does not supply a universal testing algorithm.

# Maternal endocrine disorders are a separate domain


## **Gestation also requires a supportive maternal endocrine environment**

- Robbins explicitly lists luteal-phase defect.
- Poorly controlled diabetes is also included.
- Other endocrine disorders are acknowledged but not enumerated in this passage.

The excerpt identifies endocrine etiologies without defining laboratory cutoffs.

# Luteal-phase defect: The named endocrine contributor

*Conceptual pathway (schematic)*



This is an explanatory teaching sequence. The defect but does not establish a test or individual causal pathway.

No biochemical diagnostic threshold is given in this source.

# Poorly controlled diabetes is a maternal factor

## The qualifier “poorly controlled” matters

- The named contributor is poorly controlled diabetes, not diabetes under all conditions.
- It appears under maternal endocrine etiologies.
- The excerpt does not provide glycemic thresholds, odds ratios, or management targets.

Do not imply a patient-specific risk estimate without additional evidence.

## Other endocrine disorders: A defined source limit

### The textbook acknowledges a category without naming every member

- The expression “other endocrine disorders” broadens the maternal endocrine domain.
- This excerpt does not identify which disorders qualify or their relative contributions.
- Avoid substituting a fabricated exhaustive endocrine checklist.

#### Instructional discipline

When teaching from a short excerpt, a stated information gap is preferable to an unsupported numerical or diagnostic claim.

Additional detail requires separately identified external evidence.

# Uterine anatomy can impair implantation


## The mechanism named by Robbins is mechanical disruption

- Submucosal leiomyomas and uterine polyps are examples.
- Uterine malformations provide a third structural category.
- Such lesions may prevent or disrupt implantation.

The key link is location/architecture → implantation disturbance.

# Submucosal leiomyoma: The proposed interface

*Conceptual pathway (schematic)*



Source supports a possible implantation mechanism; It does not specify lesion-size thresholds.

A leiomyoma elsewhere in the uterus is not automatically the proven cause.

## Uterine polyps are another structural example

### **A focal intrauterine lesion can affect the implantation site**

- Polyps are explicitly listed in the physical-anomaly group.
- Their relevance is conceptualized through interference with implantation.
- The passage supplies no polyp size, location rule, or comparative risk estimate.

The source establishes a possible causal category, not a numerical severity scale.

# Uterine malformations alter the implantation setting

## **The relevant feature is the overall uterine configuration**

- Congenital or other malformations are listed as structural contributors.
- They can be considered distinct from localized masses and polyps.
- The passage does not provide malformation types or outcome frequencies.

Do not invent subtype-specific pregnancy-loss rates.

# Structural factors differ in the type of abnormality

| Example              | Anatomic characterization      | Mechanism in source              |
|----------------------|--------------------------------|----------------------------------|
| Submucosal leiomyoma | Myometrial lesion near cavity  | May prevent/disrupt implantation |
| Uterine polyp        | Focal intrauterine growth      | May prevent/disrupt implantation |
| Uterine malformation | Abnormal uterine configuration | May prevent/disrupt implantation |

The shared mechanistic endpoint is implantation interference.

# Maternal vascular conditions form another domain

## **Abnormal systemic vascular status can affect gestation**

- Antiphospholipid antibody syndrome.
- Coagulopathies are named as a broader category.
- Hypertension is the third explicit example.

Vascular contributors differ from physical interruption of implantation.

# Antiphospholipid antibody syndrome is named

## **A systemic maternal disorder affecting vasculature**

- The condition appears among maternal vascular causes of miscarriage.
- The excerpt does not set laboratory persistence criteria or obstetric diagnostic criteria.
- Its recognition in a pathology framework does not replace a formal clinical diagnostic standard.

Avoid supplying unverified antibody cutoffs or treatment regimens.

# Coagulopathies: A broad vascular-risk category

**Robbins does not name a single inherited or acquired subtype here**

- Coagulopathies are explicitly included under systemic disorders affecting vasculature.
- The source does not equate all coagulation abnormalities with pregnancy loss.
- Mechanism, causality and testing details require evidence beyond the excerpt.

Do not presume every thrombophilia is causally established.

# Hypertension: A maternal systemic contributor

## The source links vascular maternal disease to pregnancy-loss etiologies

- Hypertension is the named cardiovascular example.
- The excerpt does not subdivide chronic versus pregnancy-specific hypertension.
- It does not provide a pressure threshold or risk ratio for early miscarriage.

The cause category should not be converted into a diagnostic prediction.

## Structural and vascular contributors are different

| Question             | Uterine structural domain           | Maternal vascular domain               |
|----------------------|-------------------------------------|----------------------------------------|
| Primary issue        | Anatomy / implantation setting      | Systemic vascular disorder             |
| Examples             | Fibroid, polyp, malformation        | APS, coagulopathy, hypertension        |
| Mechanistic emphasis | May prevent or disrupt implantation | Maternal vasculature affects gestation |

The two domains may coexist, but should not be treated as synonyms.

# Infectious causes include multiple pathogen classes


## Organisms without quantifying individual risks

- Protozoal infection: Toxoplasma.
- Bacterial examples: Mycoplasma and Listeria.
- Certain viruses are also recognized, without naming specific viruses in this excerpt.

A named pathogen category is not equivalent to proof of infection in a case.

# Ascending infection: Route from lower genital tract

*Conceptual pathway (schematic)*




This route is particularly common in second-trimester pregnancy loss.

Route is specified; Diagnostic microbiology criteria are not.

# Hematogenous infection: A distinct route

*Conceptual pathway (schematic)*



The source names hematogenous transmission as an alternative to ascending infection.

These pathways describe route of entry, not a uniform lesion pattern.

## Second-trimester loss: Infectious timing clue

### **Ascending lower-genital-tract infection is especially relevant**

- The source singles out ascending infection from the cervicovaginal vault.
- It calls this route a particularly common cause of second-trimester losses.
- This does not imply that every second-trimester loss is infectious.

Gestational timing provides context, not a definitive etiologic test.

## Pathogen classes and routes are distinct axes

| Axis           | Textbook examples                                 | Interpretation                        |
|----------------|---------------------------------------------------|---------------------------------------|
| Pathogen class | Toxoplasma; Mycoplasma; Listeria; certain viruses | Identifies possible agents            |
| Routes         | Ascending or hematogenous                         | Identifies access to placenta / fetus |
| Timing         | Ascending route emphasized in trimester two       | A gestational association, not proof  |

An organism, an anatomic route and a gestational interval are different kinds of evidence.

# Pregnancy requires fetal–maternal immune tolerance


## **The fetal–placental unit is described as a hemi-allograft**

- Fetal-derived cells are immunologically distinct from the mother.
- Successful gestation therefore requires limitation of harmful immune rejection.
- The source links tolerance to trophoblast invasion of the maternal uterus.

Immune tolerance is a normal, active requirement—not absence of an immune system.

# Trophoblast invasion requires regulated tolerance

*Conceptual pathway (schematic)*



The source describes coordinated tolerance of the invasive fetal placental cells.

This is an explanatory schematic of the source narrative.

# Innate and adaptive immunity may be involved

## Two components of maternal immune regulation are implicated

- Disturbed innate immunity may contribute in some cases.
- Adaptive immune abnormalities are also implicated.
- The evidence is framed as emerging and mechanistically incomplete.

The excerpt does not supply an immune biomarker panel or validated test cutoff.

# Regulatory T-cell dysfunction is a candidate mechanism

## A specific immunologic example in recurrent loss

- Regulatory T cells are explicitly identified in the source.
- Defective function may participate in recurrent spontaneous abortion in some females.
- The textbook does not establish that this accounts for all recurrent losses.

A candidate mechanism is not a universal, clinically proven diagnostic explanation.

# Recurrent miscarriage is etiologically important

## **The source specifically connects recurrence and immune imbalance**

- The immunologic paragraph discusses recurrent spontaneous abortion.
- Its language is conditional: Such defects “may underlie” some cases.
- The same source also acknowledges multiple genetic and maternal contributors.

Avoid assuming an immune cause solely because a loss recurs.

# Immune pathogenesis remains incompletely understood

## **Do not present a speculative pathway as settled disease biology**

- The source explicitly characterizes the mechanisms as poorly understood.
- Innate/adaptive disturbances and T-cell dysfunction are evidence-based hypotheses.
- No immune-based testing or treatment protocol is established in the supplied excerpt.

**Scientific uncertainty should appear in teaching, not be suppressed.**

## Evidence strength varies across source statements

| Source statement                                  | Degree of specification           | Appropriate teaching phrasing         |
|---------------------------------------------------|-----------------------------------|---------------------------------------|
| Chromosomal anomalies in ~50% early abortuses     | Quantified association            | Approximately half of early abortuses |
| Uterine abnormality may disrupt implantation      | Qualitative mechanism             | Possible structural contributor       |
| T-regulatory dysfunction in some recurrent losses | Conditional, incomplete mechanism | May contribute in a subset            |

Match the certainty of the lecture claim to the certainty of the text.

# Gestational timing: What can and cannot be inferred

| Observation                          | Supported reading              | Not justified                       |
|--------------------------------------|--------------------------------|-------------------------------------|
| Most losses <12 wk                   | Early predominance overall     | Specific etiology for an individual |
| Ascending infection in trimester two | Route especially relevant then | All later losses are infectious     |
| Genetic anomalies in early abortuses | Prominent early fetal category | No maternal contribution possible   |

Timing changes the reasoning context but does not identify the cause.

# Teaching vignette: Early loss and fetal genetics

## A pregnancy ends early; Fetal tissue has an abnormal chromosome complement

- Which major source category does the tissue finding support?
- Answer: Fetal chromosomal abnormality.
- Do not infer a specific cause of a parental chromosome abnormality or a recurrence probability from this excerpt.

### Interpretive distinction

A tissue result supports a mechanistic category, but does not by itself establish counseling recommendations.

The case is hypothetical; No clinical dataset is presented.

# Teaching vignette: Implantation and uterine anatomy

## **A uterine cavity has a submucosal mass, followed by an early pregnancy loss**

- Which category is relevant? Physical anomaly of the uterus.
- What mechanism is specifically offered? Prevention or disruption of implantation.
- What is not established? That the lesion certainly caused the loss.

An association compatible with the source is not a proven individual causal chain.

# Teaching vignette: Loss in the second trimester

## **A pregnancy loss follows an ascending cervicovaginal infection**

- Which route fits the source? Ascending genital-tract spread.
- Why is timing relevant? This route in second-trimester losses.
- Why is a pathogen still not identified? Route alone is not microbiologic proof.

Route, organism and gestational timing must be distinguished.

# Teaching vignette: Recurrent losses and immunity

## Several losses prompt consideration of fetal–maternal tolerance

- What immunologic concepts are raised? Innate and adaptive regulation.
- Which named cell population? Regulatory T cells.
- Does recurrence prove immune rejection? No; The mechanism is incompletely understood.

Recurrent loss cannot be assigned to immunity by default.

## Four clinical clues map to different domains

| Clue in vignette       | Mechanistic domain   | Source limit                            |
|------------------------|----------------------|-----------------------------------------|
| Chromosome abnormality | Fetal genomic        | Not all losses are genetic              |
| Submucosal mass        | Uterine structural   | May disrupt implantation                |
| Ascending infection    | Infectious route     | Agent not proved by route               |
| Recurrent loss         | Possible immunologic | Conditional and incompletely understood |

## Do not overstate the scope of this excerpt


### The topic is etiologic pathology, not a treatment guideline

- No ultrasound viability criteria, serial hCG cutoffs or management algorithm are supplied.
- No universal pathognomonic miscarriage morphology is documented.
- No treatment dose, laboratory diagnostic panel or recurrence probability is provided.

**Additional clinical guidelines must be separately sourced before adding those claims.**

# Independent mechanisms can converge on pregnancy loss

*Conceptual etiologic framework — parallel contributors, not a causal sequence*



These are alternative domains; The textbook does not establish a unique cause for most individual early losses.

# Core synthesis: Five exam-relevant distinctions

## Translate the pathology excerpt into defensible statements

- Recognized versus assay-detected early loss: Detection changes observed frequency.
- Aneuploidy versus polyploidy versus translocation: Different genetic abnormalities.
- Structural versus vascular maternal factors: Distinct etiologic domains.
- Ascending versus hematogenous infection: Distinct placental access routes.
- Tolerance biology versus established immune causation: Avoid overstatement.

## Assessment: Match source statement to mechanism

| Clinical or textual finding                         | Most appropriate domain                  |
|-----------------------------------------------------|------------------------------------------|
| Abnormal fetal chromosome count                     | Fetal chromosomal abnormality            |
| Submucosal leiomyoma affecting implantation         | Uterine structural                       |
| Antiphospholipid antibody syndrome                  | Maternal vascular                        |
| Cervicovaginal ascending infection                  | Infectious                               |
| T-regulatory-cell defect proposed in recurrent loss | Possible maternal–fetal immune imbalance |

The table tests recognition, not case-specific causation.

# Core source and scope

## Primary reading

- Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th edition (2026).
- Chapter 22, The Female Genital Tract; 'Spontaneous Abortion,' printed pp. 934–935.
- Anatomical context: 'Gestational and Placental Disorders,' printed pp. 933–934; Fig. 22.44 descriptive caption.

No copyrighted textbook photographs are reproduced. All teaching graphics are editable native schematics.